Floatz logo

BMS-986345

T-cell Prolymphocytic Leukemia

Jonsson Comprehensive Cancer CenterPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the T-cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Ruxolitinib
Jonathan Brammer
Phase 2B
Duvelisib
Jonsson Comprehensive Cancer Center
Phase 1/2CCC
Anti-Cd7 Car-Pnk Cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2CC
Itacitinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1CC

Same molecule, other indications

BMS-986345 is also rated in:

Chronic Lymphocytic LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Follicular LymphomaDormant
B
Indicative ·
56 / 100
View asset →
Indolent Non-Hodgkin LymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →